Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6

被引:0
|
作者
Ryota Tanaka
Yuki Ichimura
Noriko Kubota
Akimasa Saito
Yoshiyuki Nakamura
Yosuke Ishitsuka
Rei Watanabe
Yasuhiro Fujisawa
Mirei Kanzaki
Seiya Mizuno
Satoru Takahashi
Manabu Fujimoto
Naoko Okiyama
机构
[1] Faculty of Medicine,Department of Dermatology
[2] University of Tsukuba,Department of Dermatology
[3] Graduate School of Medicine Faculty of Medicine,Department of Dermatology
[4] Osaka University,Laboratory Animal Resource Center, Faculty of Medicine
[5] Mito Saiseikai General Hospital,undefined
[6] University of Tsukuba,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Use of immune checkpoint inhibitors that target programmed cell death-1 (PD-1) can lead to various autoimmune-related adverse events (irAEs) including psoriasis-like dermatitis. Our observations on human samples indicated enhanced epidermal infiltration of CD8 T cells, and the pathogenesis of which appears to be dependent on IL-6 in the PD-1 signal blockade-induced psoriasis-like dermatitis. By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6. Moreover, genetically modified mice lacking PD-1 expression only on CD8 T cells developed accelerated dermatitis, moreover, blockade of IL-6 signaling by anti-IL-6 receptor antibody could ameliorate the dermatitis. Collectively, PD-1 signal blockade-induced psoriasis-like dermatitis is mediated by PD-1 signaling on CD8 T cells, and furthermore, IL-6 is likely to be a therapeutic target for the dermatitis.
引用
收藏
相关论文
共 50 条
  • [41] T-CELL ACTIVATION IN PSORIASIS AND ATOPIC-DERMATITIS - SERUM LEVELS OF INTERLEUKIN-2 RECEPTOR AND CD8 LIKE MOLECULE
    KAPP, A
    CLINICAL RESEARCH, 1989, 37 (02): : A661 - A661
  • [42] Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells
    Bae, Eun-Ah
    Seo, Hyungseok
    Kim, Byung-Seok
    Choi, Jeongwon
    Jeon, Insu
    Shin, Kwang-Soo
    Koh, Choong-Hyun
    Song, Boyeong
    Kim, Il-Kyu
    Min, Byung Soh
    Han, Yoon Dae
    Shin, Sang Joon
    Kang, Chang-Yuil
    CANCER RESEARCH, 2018, 78 (18) : 5315 - 5326
  • [43] CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice
    Yasuda, Yoshinori
    Iwama, Shintaro
    Sugiyama, Daisuke
    Okuji, Takayuki
    Kobayashi, Tomoko
    Ito, Masaaki
    Okada, Norio
    Enomoto, Atsushi
    Ito, Sachiko
    Yan, Yue
    Sugiyama, Mariko
    Onoue, Takeshi
    Tsunekawa, Taku
    Ito, Yoshihiro
    Takagi, Hiroshi
    Hagiwara, Daisuke
    Goto, Motomitsu
    Suga, Hidetaka
    Banno, Ryoichi
    Takahashi, Masahide
    Nishikawa, Hiroyoshi
    Arima, Hiroshi
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (593)
  • [44] CD8+T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
    Huseni, Mahrukh A.
    Wang, Lifen
    Klementowicz, Joanna E.
    Yuen, Kobe
    Breart, Beatrice
    Orr, Christine
    Liu, Li-fen
    Li, Yijin
    Gupta, Vinita
    Li, Congfen
    Rishipathak, Deepali
    Peng, Jing
    Senbabaoglu, Yasin
    Modrusan, Zora
    Keerthivasan, Shilpa
    Madireddi, Shravan
    Chen, Ying-Jiun
    Fraser, Eleanor J.
    Leng, Ning
    Hamidi, Habib
    Koeppen, Hartmut
    Ziai, James
    Hashimoto, Kenji
    Fasso, Marcella
    Williams, Patrick
    McDermott, David F.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Emens, Leisha A.
    Hegde, Priti S.
    Mellman, Ira
    Turley, Shannon J.
    Wilson, Mark S.
    Mariathasan, Sanjeev
    Molinero, Luciana
    Merchant, Mark
    West, Nathaniel R.
    CELL REPORTS MEDICINE, 2023, 4 (01)
  • [45] Combination treatment with recombinant murine IL-12 and anti-PD-1 antibody enhanced anti-tumor efficacy through the activation of cytotoxic T cell response
    Yang, Yeng-Jey
    Tsou, Pei-Yi
    Chou, Shiuh-Dih
    Lee, Meng-Na
    Chen, San-Chi
    CANCER RESEARCH, 2023, 83 (07)
  • [46] An anti-CD4 antibody protects mice from anti-PD-1/PDL-1 antibody-induced fatal anaphylaxis and shows potent anti-metastatic activity in the 4T1 spontaneous metastasis model
    Ito, Satoru
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Ueha, Satoshi
    Shand, Francis
    Matsushima, Kouji
    CANCER RESEARCH, 2016, 76
  • [47] Entinostat synergizes with the IL-15 superagonist N-803 and anti-PD-1 to engage cDC1 and stem-like TCF-1+CD8+T and NK cells to overcome colorectal tumors refractory to anti-PD-1 therapy
    Minnar, Christine M.
    Miyamoto, Masaya
    Khelifa, Asma S.
    Lui, Grace
    Lothstein, Katherine L.
    Chariou, Paul L.
    Meyer, Thomas J.
    Lobanov, Alexei
    Cam, Margaret
    Schlom, Jeffrey
    Gameiro, Sofia R.
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Resistance to anti-PD-1 therapy is associated with the retention of CXCR3+CD4+CD8-T cells in blood
    Han, X.
    Tan, T.
    Sun, J.
    Chen, X.
    Cai, X.
    Lin, P.
    Tan, Y.
    Wang, B.
    Wang, Y.
    Wang, J.
    Yu, Z.
    Wu, X.
    Xu, Q.
    Gu, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+T cells via pharmacological activation of FOXO3
    Chung, Young Min
    Khan, Pragya P.
    Wang, Hong
    Tsai, Wen-Bin
    Qiao, Yanli
    Yu, Bo
    Larrick, James W.
    Hu, Mickey C-T
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
  • [50] Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell
    Zhu, Xinhai
    Li, Ke
    Liu, Guichao
    Wu, Ruan
    Zhang, Yan
    Wang, Siying
    Xu, Meng
    Lu, Ligong
    Li, Peng
    GUT MICROBES, 2023, 15 (02)